uniQure (NASDAQ:QURE) Shares Gap Up After Analyst Upgrade

uniQure N.V. (NASDAQ:QURE) gapped up before the market opened on Monday after Chardan Capital raised their price target on the stock from $16.00 to $31.00. The stock had previously closed at $14.27, but opened at $18.02. Chardan Capital currently has a buy rating on the stock. uniQure shares last traded at $16.1640, with a volume of 5,988,132 shares.

QURE has been the subject of a number of other reports. William Blair reissued a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. Barclays assumed coverage on shares of uniQure in a research note on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 price target for the company. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and increased their price objective for the company from $11.00 to $35.00 in a research report on Monday. TD Cowen restated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Finally, The Goldman Sachs Group decreased their price objective on shares of uniQure from $37.00 to $9.00 and set a “neutral” rating for the company in a research report on Tuesday, March 3rd. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $41.33.

Insider Activity at uniQure

In other news, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $30,912.72. Following the completion of the sale, the insider owned 138,483 shares in the company, valued at approximately $1,254,655.98. The trade was a 2.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christian Klemt sold 12,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $108,720.00. Following the completion of the transaction, the chief financial officer owned 226,581 shares of the company’s stock, valued at approximately $2,052,823.86. The trade was a 5.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 81,399 shares of company stock valued at $1,527,645 in the last quarter. Company insiders own 4.79% of the company’s stock.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Analyst upgrades and price‑target increases lifting sentiment — Wells Fargo upgraded QURE to “overweight” with a $60 PT and Chardan boosted its PT to $31 with a buy rating; RBC moved to “outperform” with a $35 PT. These calls drove constructive re‑ratings and buy-side interest. Wells Fargo Upgrade Chardan PT Raise
• Positive Sentiment: Regulatory leadership change in the FDA (CBER director Vinay Prasad’s announced exit) is being interpreted by the market as easing near‑term regulatory risk for gene‑therapy programs, prompting a sector rally that lifted uniQure shares. Blockonomi: Stock Soars on FDA Exit Benzinga: Biotech Reaction
• Neutral Sentiment: Analyst and media coverage is spotlighting uniQure ahead of key AMT‑130 catalysts; these pieces increase visibility but do not change fundamentals absent clinical or regulatory news. 24/7 Wall St. Analyst Interest
• Negative Sentiment: Multiple law firms have filed or publicized investor notices seeking lead plaintiffs for a securities class action covering Sept. 24–Oct. 31, 2025 (claims tied to AMT‑130 disclosures). The proliferation of filings (Faruqi, Hagens Berman, Levi & Korsinsky, Portnoy, Rosen) creates legal and disclosure risk and could impose costs or settlement pressure. Faruqi & Faruqi Notice Hagens Berman Alert Levi & Korsinsky Notice Portnoy Law Firm Rosen Law Firm Notice
• Negative Sentiment: Coverage highlighting “confusion” and shifting narratives around uniQure’s disputes with the FDA over AMT‑130 suggests ongoing regulatory uncertainty that could weigh on valuation until resolved. The Pharma Letter: Confusion Grows Yahoo Finance: Shifting Narrative

Institutional Trading of uniQure

Hedge funds and other institutional investors have recently made changes to their positions in the company. Private Trust Co. NA acquired a new stake in shares of uniQure in the 3rd quarter valued at about $28,000. Torren Management LLC acquired a new position in uniQure during the fourth quarter worth approximately $28,000. Jones Financial Companies Lllp increased its position in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the period. IFP Advisors Inc purchased a new stake in uniQure in the fourth quarter valued at approximately $48,000. Finally, Smartleaf Asset Management LLC acquired a new stake in shares of uniQure in the fourth quarter valued at approximately $48,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Price Performance

The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -5.21 and a beta of 0.73. The company has a fifty day moving average price of $21.90 and a two-hundred day moving average price of $29.64.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.37. The firm had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. On average, equities research analysts expect that uniQure N.V. will post -3.75 EPS for the current fiscal year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.